These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8106059)

  • 1. [A screening model for selecting atypical anxiolytics].
    Asrian AB; Dzhagatspanian IA
    Eksp Klin Farmakol; 1993; 56(4):58-60. PubMed ID: 8106059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effect of different anxiolytics on the anxiety state occurring in rats after stopping the electrical stimulation of the dorsal hippocampus].
    Beĭer EV; Arushanian EB
    Eksp Klin Farmakol; 1999; 62(5):7-10. PubMed ID: 10572742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Behavioral models of anxiety in animals].
    Thiebot MH
    Encephale; 1983; 9(4 Suppl 2):167B-176B. PubMed ID: 6144511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The light-enhanced startle paradigm as a putative animal model for anxiety: effects of chlordiazepoxide, flesinoxan and fluvoxamine.
    de Jongh R; Groenink L; van Der Gugten J; Olivier B
    Psychopharmacology (Berl); 2002 Jan; 159(2):176-80. PubMed ID: 11862346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The anxiolytic activity of calcium-channel blockers in tests of anxious behavior in mice and rats].
    Kozlovskiĭ VL
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1999; 49(1):84-95. PubMed ID: 10330709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of typical and atypical anxiolytics on the behavior and electrophysiological parameters of rats with model cerebrovascular pathology].
    Molodavkin GM; Cadikov MK; Voronina TA; Sadikova ZU; Meletova OK; Pchelkina MI; Larentsova LI; Gan'shina TS; Mirzoian RS
    Eksp Klin Farmakol; 2004; 67(6):16-9. PubMed ID: 15707007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dependence of the strength of anxiolytic effect of tranquilizers on the level of anxiety in a conflict situation].
    Molodavkin GM; Voronina TA
    Biull Eksp Biol Med; 1996 Jan; 121(1):63-6. PubMed ID: 8680009
    [No Abstract]   [Full Text] [Related]  

  • 8. [The neurochemical profile of the dorsal hippocampus and the antiaversive effects of anxiolytics in different models of anxiety in rats].
    Talalaenko AN
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1993; 43(3):621-6. PubMed ID: 8103252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The characteristics of the anxiolytic action of benzodiazepine and non-benzodiazepine tranquilizers in different tests of anxiety].
    Talalaenko AN; Abramets II; Stakhovskiĭ IuV; Shekhovtsov AA; Shevchenko SL; Chernikov AV
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1992; 42(1):144-51. PubMed ID: 1349783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparative characteristics of the psychotropic activity of "atypical" tranquilizers in an experiment].
    Rudenko GM; Chemesov IuV; Garibova TL; Voronina TA
    Farmakol Toksikol; 1983; 46(3):26-9. PubMed ID: 6134635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioral effects of sinomenine in murine models of anxiety.
    Chen SW; Mi XJ; Wang R; Wang WJ; Kong WX; Zhang YJ; Li YL
    Life Sci; 2005 Dec; 78(3):232-8. PubMed ID: 16111714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The neurochemical profile of the septal nucleus accumbens in the anxiolytic action of tranquilizers on different models of anxiety].
    Talalaenko AN; Panfilov VIu; Vozdigan SA; Pokramovich AI; Markova OP; Okhrimenko SV
    Eksp Klin Farmakol; 1997; 60(4):7-9. PubMed ID: 9376765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Arousal and the psychopharmacology of anxiety in experimental models].
    Kaluev AV; Nutsa NA
    Eksp Klin Farmakol; 1998; 61(5):69-74. PubMed ID: 9854641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anxiolytic-like effect of group III mGlu receptor antagonist is serotonin-dependent.
    Stachowicz K; Chojnacka-Wójcik E; Kłak K; Pilc A
    Neuropharmacology; 2007 Feb; 52(2):306-12. PubMed ID: 17020774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mCPP-induced anxiety--a potential new method for screening anxiolytic activity.
    Bilkei-Gorzó A; Gyertyán I; Szabados T
    Neurobiology (Bp); 1996; 4(3):253-5. PubMed ID: 9044356
    [No Abstract]   [Full Text] [Related]  

  • 16. [The effect of calcium channel blockers on anxiety evoked by amputation of the vibrissae in rats].
    Kozlovskiĭ VL; Mosin AE; Ivakina LV
    Eksp Klin Farmakol; 1997; 60(1):10-2. PubMed ID: 9162271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of angelica essential oil in three murine tests of anxiety.
    Chen SW; Min L; Li WJ; Kong WX; Li JF; Zhang YJ
    Pharmacol Biochem Behav; 2004 Oct; 79(2):377-82. PubMed ID: 15501315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The influence of calcium channel blockers on the effects of anxiogenic preparations].
    Kozlovskiĭ VL
    Patol Fiziol Eksp Ter; 2000; (3):3-4. PubMed ID: 10983469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An assessment of anxiolytic drug screening tests: hormetic dose responses predominate.
    Calabrese EJ
    Crit Rev Toxicol; 2008; 38(6):489-542. PubMed ID: 18615308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The anxiolytic effect of ondansetron and its capacity to eliminate the benzodiazepine abstinence syndrome in rats].
    Garibova TL; Voronina TA; Kraĭneva VA; Val'dman EA
    Eksp Klin Farmakol; 1999; 62(6):16-9. PubMed ID: 10650519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.